Quick Answer
SANGAMO THERAPEUTICS, INC reported Cash and Equivalents of $20.95 million for fiscal year 2025.
SANGAMO THERAPEUTICS, INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $20.95M | -50.0% |
| 2024 | $41.92M | -7.3% |
| 2023 | $45.20M | -55.0% |
| 2022 | $100.44M | -43.8% |
| 2021 | $178.87M | +36.2% |
| 2020 | $131.33M | +63.3% |
| 2019 | $80.43M | -42.7% |
| 2018 | $140.42M | +181.8% |
| 2017 | $49.83M | +125.9% |
| 2016 | $22.06M | -68.2% |
| 2015 | $69.48M | +1052.3% |
| 2014 | $6.03M | -40.8% |
| 2013 | $10.19M | -53.0% |
| 2012 | $21.68M | +29.3% |
| 2011 | $16.77M | +55.5% |
| 2010 | $10.78M | -49.0% |
| 2009 | $21.16M | +9.0% |
| 2008 | $19.41M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $29.62M | -24.5% | -22.8% |
| June 30, 2025 | $38.34M | +38.0% | +52.3% |
| March 31, 2025 | $25.18M | -53.7% | -39.9% |
| December 31, 2024 | $41.92M | -7.3% | +6.9% |
| September 30, 2024 | $39.20M | -30.6% | +41.1% |
| June 30, 2024 | $27.79M | -58.4% | -48.9% |
| March 31, 2024 | $54.42M | -30.4% | +20.4% |
| December 31, 2023 | $45.20M | -55.0% | -20.0% |
- SANGAMO THERAPEUTICS, INC showed a decrease of -50.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, SANGAMO THERAPEUTICS, INC’s cash and equivalents has grown by 7.9% (from $19.41 million to $20.95 million).
- The most recent figure is from SANGAMO THERAPEUTICS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: